Business
OWC Pharma Issues Chairman's Letter to Shareholders
OWC Pharma Issues Chairman's Letter to Shareholders.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharma Issues Chairman's Letter to Shareholders\n\n\n\n\n\nOWC Pharma Issues Chairman's Letter to Shareholders\nPR Newswire\nPETACH TIKVA, Israel, September 14, 2017\n\n\n\nPETACH TIKVA, Israel, September 14, 2017 /PRNewswire/ --\n\nOWC Pharma (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders.\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )\n\n\nLetter from the Chairman,\n\nTo our Shareholders,\n\n\nFollowing my recent appointment as Chairman at OWC Pharma (OTCQB: OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.\n\n\nOn the personal front, I am a biologist by training with a D. Phil. Degree from Oxford University in Cell Biology and Immunology. I have been involved in diagnostics, pharmaceutical and biotechnology (medical and agricultural) companies at CEO level since 1989 and I have run both private and public companies in this sector in Brazil, China, England, Israel and the United States. My roles in these companies have included operational and strategic elements. I currently serve as CEO of FuturaGene Ltd., an agricultural biotech company. I have been the manager of the company since its inception, leading it through a series of private fundings, a reverse merge on the AIM Exchange of the London Stock Market, a successful secondary offering in London and the ultimate sale of the company to Suzano Pulp and Paper in Brazil in a cash transaction which valued the company at US $100 million. As CEO of FuturaGene, I successfully obtained the first ever regulatory approval to commercially deploy a genetically modified commercial tree species. In addition to my role as Chairman at OWC Pharma, I also currently serve as Chairman at Foamix Pharmaceuticals (NASDAQ: FOMX), a specialty dermatology company, inter alia.  In my early years as an Executive Director at Foamix, I was responsible for European Business Development, and in this role, I cemented an out-licensing deal with Bayer Pharmaceuticals for the development and commercialization of a topical drug for Rosacea. Marketing of this drug was initiated in late 2015 after FDA approval and today yields multi-million dollar annual ro...